


Final Recruitment:

- ICARUS has recruited a total of **4125** participants across **13 sites worldwide**, a huge achievement!
- Belgium, Canada, London, New York, Sweden, Chicago and Miami have finished sample collection.
- All other sites will be finishing soon.

We would like to thank you for all your hard work and enthusiasm on the study and we are looking forward to sharing the data with you!

**2 year extension:**

The proposal to extend the study for 2 years was submitted to The Helmsley on 29th May.

The proposal has been circulated to all sites and we will update you on the outcome when it becomes available.

Final timepoint sample and data deadline:

Many sites have now finished sample collection for the existing study and we are now focusing on getting the data for the 3rd and final timepoint which we are aiming to be approximately 1 month post booster vaccination.

Here, in Oxford, we would like to receive these samples for testing at the end of May along with the clinical data. In New York, the testing for this timepoint will begin at the same time.

Minimal datasets are required from those sites who do not use REDCAP. We kindly ask for these to be completed in good time to allow data cleaning to commence.

If you have any questions, [please do get in touch!](#)

DDW:

Matthew Edmans will be attending DDW at the end of May and will be both presenting the ICARUS data and overseeing the poster.

Presentation: Both Vedolizumab and infliximab therapy are associated with attenuation of serological and neutralizing responses to sars-cov-2 infection in inflammatory bowel disease: report from the ICARUS-IBD consortium.

Poster: Trans-continental analysis of over 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium.